TL;DR: Tirzepatide and Cagrilintide attack body-weight regulation from completely different angles. Tirzepatide is a dual GIP/GLP-1 incretin agonist with the strongest standalone weight-loss data in the peptide universe. Cagrilintide is a long-acting amylin analogue that suppresses appetite and slows gastric emptying without touching incretin pathways. They are complementary, not interchangeable — most modern protocols stack them.
TL;DR — quick comparison table
| Dimension | Tirzepatide | Cagrilintide |
|---|---|---|
| Receptor targets | GIP + GLP-1 (dual incretin) | Amylin + Calcitonin (amylin analogue) |
| Peak weight loss (mono) | ~22.5% at 72 weeks (SURMOUNT-1) | ~10.8% at 26 weeks (Lau et al., Lancet) |
| Trial stage | Phase 3 complete | Phase 2 complete; phase 3 (REDEFINE) ongoing |
| Typical reference dose | 2.5 mg week, titrate to 15 mg weekly | 0.3 mg week, titrate to 2.4 mg weekly |
| Common side effects | Nausea, mild GI, decreased appetite | Mild nausea, injection-site reactions |
| PH availability | Widely available | Available; smaller supplier base |
| Noki Labs price | ₱2,000–₱3,500 | ₱2,200 (10mg vial) |
| Best for | Maximum monotherapy efficacy | GI-sensitive individuals, plateau-breaker, stack partner |
How each peptide works (the science)
Tirzepatide: dual incretin amplification
Tirzepatide simultaneously activates GIP and GLP-1 receptors, which means it amplifies post-meal insulin secretion, slows gastric transit, and dampens hypothalamic appetite drive. The dual mechanism is what produces the steepest weight-loss curve in any approved single-molecule incretin therapy. It also carries the standard incretin GI profile.
Cagrilintide: amylin signaling, no incretin overlap
Cagrilintide is a long-acting amylin analogue. Amylin is a hormone co-secreted with insulin that signals satiety, slows gastric emptying, and suppresses post-prandial glucagon — a mechanism orthogonal to the GLP-1 family. Because Cagrilintide doesn't touch GIP or GLP-1, it can be combined with Tirzepatide without redundant pathway saturation. As a monotherapy, its effect size is more modest — around 10–11% body weight loss at 26 weeks — but with notably lower GI burden.
Clinical evidence — head to head
Tirzepatide: SURMOUNT-1 (Jastreboff et al., NEJM 2022) showed mean weight reduction of 20.9% at 15 mg weekly across 72 weeks.
Cagrilintide: Lau et al. (Lancet 2021) reported 10.8% weight loss at 2.4 mg over 26 weeks vs. 9.0% for liraglutide — superior to a GLP-1 monotherapy at matched duration.
The more compelling story is the combination. CagriSema-class data (Frias et al., 2023) demonstrated 15.6% weight loss at 32 weeks for the cagrilintide+semaglutide combination, with a curve trending well beyond what either monotherapy achieved — directly motivating the Tirzepatide + Cagrilintide stacking protocols now in use.
Cost in the Philippines
Reference prices: Atlas Compounds Retatrutide ~₱7,899/vial; MedsGo Tirzepatide ~₱5,985/vial. A 12-week titrated protocol costs:
| Protocol | Noki Labs total (12 weeks) |
|---|---|
| Tirzepatide mono (titrated to 10 mg) | ~₱16,800 |
| Cagrilintide mono (titrated to 2.4 mg) | ~₱8,800 |
| Tirzepatide + Cagrilintide stack | ~₱25,600 |
Noki Labs prices Cagrilintide 10 mg at ₱2,200, the most affordable verified-COA option in the Philippines. Apply BULK20 on stack orders for 20% off.
Side effects — what's different
Tirzepatide carries the classical incretin signature: nausea (peak weeks 2–6 after each titration step), occasional vomiting, mild constipation. Cagrilintide is consistently rated milder on GI by trial participants — the most common report is mild nausea at the highest dose, plus occasional injection-site redness. There is no incretin-typical "food revulsion" effect with Cagrilintide; appetite reduction is steadier and more subtle.
Which is better for [persona/goal]?
If you're new to GLP-1 peptides
Tirzepatide as monotherapy. Better data, more dosing literature.
If you want maximum weight loss
Stack them. Cagrilintide alone caps at ~11%; Tirzepatide alone caps at ~22.5%. The stack pushes meaningfully past the upper Tirzepatide ceiling without doubling GI burden.
If you have GI sensitivity
Cagrilintide as a starter. Slow titration, lower nausea, and you can later add Tirzepatide once tolerance is established.
If you're plateauing on Tirzepatide
Add Cagrilintide rather than pushing to 15 mg Tirzepatide. The amylin pathway is fresh territory for the body and often re-engages weight loss.
Stacking Tirzepatide with Cagrilintide
The protocol is well-mapped. Run Tirzepatide on its own titration schedule (2.5 → 5 → 7.5 → 10 mg weekly), and after week 4, layer Cagrilintide starting at 0.3 mg weekly, titrating every 4 weeks to a 2.4 mg ceiling. Inject on different days to spread GI exposure. Full protocol detail lives in our Tirzepatide + Cagrilintide Stack Guide.
Where to buy in the Philippines
Both peptides are stocked at Noki Labs PH:
- Tirzepatide: /products/tirzepatide — ₱2,000–₱3,500, 4 variants
- Cagrilintide: /products/cagrilintide — ₱2,200, 10 mg vial
Browse the full weight-management collection for related compounds. Manila customers can review shipping detail at /pages/peptide-supplier-manila. See depth on each pillar at /pages/tirzepatide-philippines and /pages/cagrilintide-philippines.
FAQ
Q: Is Cagrilintide a GLP-1? No. It's an amylin analogue, a different class entirely.
Q: Can I run Cagrilintide solo? Yes, with the understanding that mono-data caps near 11% body-weight reduction.
Q: Does Cagrilintide cause nausea? Less than Tirzepatide. Most users report only mild nausea at top dose.
Q: How is Cagrilintide stored? Reconstituted, refrigerated 2–8°C, used within 28 days.
Q: Why stack instead of just upping Tirzepatide? The amylin pathway is independent, so stacking adds effect without saturating one receptor system.
Always consult a licensed healthcare provider before starting any new peptide or wellness regimen. Individual results vary. Statements about our products are educational and not intended to diagnose, treat, cure, or prevent any disease.
Last reviewed: May 2026 · Read more in our FAQ